Collectively, our data revealed two different types of TME modification in ALK- and EGFR-positive NSCLC, respectively, which we term Treg-modulated and CD8-modulated immune TME, each accompanied by a specific characteristic of cytokine signaling. The gene discussed is CD8A; the disease is non-small cell lung carcinoma.